Pain Management Therapeutics Market (By Drug Class: NSAIDs, Opioids, Anesthetics, Antidepressants, Anticonvulsants, and Others; By Indication: Arthritic Pain, Neuropathic Pain, Chronic Back Pain, Post-Operative Pain, Cancer Pain, and Others; By Distribution Channel: Online Pharmacy, Retail Pharmacy, and Hospital Pharmacy) - Global Industry Analysis, Market Size, Share, Growth, Trends, Regional Outlook and Forecasts, 2021 - 2030

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Pain Management Therapeutics Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Pain Management Therapeutics Market

5.1. Covid-19: Pain Management Therapeutics Industry Impact
5.2. Pain Management Therapeutics Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Pain Management Therapeutics Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Pain Management Therapeutics Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Pain Management Therapeutics Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Growing prevalence of chronic disorders
6.1.1.2. Increasing geriatric population
6.1.2. Market Restraints
6.1.2.1. Side-effects associated with some pain management medications
6.1.3. Market Opportunities
6.1.3.1. Growing research and development expenditure
6.1.3.2. Technological advancements

Chapter 7. Global Pain Management Therapeutics Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Pain Management Therapeutics Market Revenue by Market Players (2016 -2019)
7.1.1.2. Pain Management Therapeutics Market Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Drug Class Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Pain Management Therapeutics Market, By Drug Class

8.1. Pain Management Therapeutics Market, by Drug Class, 2017 - 2030
8.1.1. NSAIDs
8.1.1.1. Market Revenue and Forecast (2017 - 2030)
8.1.2. Opioids
8.1.2.1. Market Revenue and Forecast (2017 - 2030)
8.1.3. Anesthetics
8.1.3.1. Market Revenue and Forecast (2017 - 2030)
8.1.4. Antidepressants
8.1.4.1. Market Revenue and Forecast (2017 - 2030)
8.1.5. Anticonvulsants
8.1.5.1. Market Revenue and Forecast (2017 - 2030)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2017 - 2030)

Chapter 9. Global Pain Management Therapeutics Market, By Indication

9.1. Pain Management Therapeutics Market, by Indication, 2017 - 2030
9.1.1. Arthritic Pain
9.1.1.1. Market Revenue and Forecast (2017 - 2030)
9.1.2. Neuropathic Pain
9.1.2.1. Market Revenue and Forecast (2017 - 2030)
9.1.3. Chronic Back Pain
9.1.3.1. Market Revenue and Forecast (2017 - 2030)
9.1.4. Post-Operative Pain
9.1.4.1. Market Revenue and Forecast (2017 - 2030)
9.1.5. Cancer Pain
9.1.5.1. Market Revenue and Forecast (2017 - 2030)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2017 - 2030)

Chapter 10. Global Pain Management Therapeutics Market, By Distribution Channel

10.1. Pain Management Therapeutics Market, by Distribution Channel, 2017 - 2030
10.1.1. Online Pharmacy
10.1.1.1. Market Revenue and Forecast (2017 - 2030)
10.1.2. Retail Pharmacy
10.1.2.1. Market Revenue and Forecast (2017 - 2030)
10.1.3. Hospital Pharmacy
10.1.3.1. Market Revenue and Forecast (2017 - 2030)

Chapter 11. Global Pain Management Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Drug Class(2017 - 2030)
11.1.2. Market Revenue Forecast by Indication(2017 - 2030)
11.1.3. Market Revenue Forecast by Distribution Channel (2017 - 2030)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2017 - 2030)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2017 - 2030)
11.2. Europe
11.2.1. Market Revenue Forecast by Drug Class (2017 - 2030)
11.2.2. Market Revenue Forecast by Indication (2017 - 2030)
11.2.3. Market Revenue Forecast by Distribution Channel (2017 - 2030)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2017 - 2030)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2017 - 2030)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2017 - 2030)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2017 - 2030)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Drug Class (2017 - 2030)
11.3.2. Market Revenue Forecast by Indication (2017 - 2030)
11.3.3. Market Revenue Forecast by Distribution Channel (2017 - 2030)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2017 - 2030)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2017 - 2030)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2017 - 2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2017 - 2030)
11.4. LATAM
11.4.1. Market Revenue Forecast by Drug Class (2017 - 2030)
11.4.2. Market Revenue Forecast by Indication (2017 - 2030)
11.4.3. Market Revenue Forecast by Distribution Channel (2017 - 2030)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2017 - 2030)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2017 - 2030)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Drug Class (2017 - 2030)
11.5.2. Market Revenue Forecast by Indication (2017 - 2030)
11.5.3. Market Revenue Forecast by Distribution Channel (2017 - 2030)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2017 - 2030)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2017 - 2030)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2017 - 2030)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2017 - 2030)

Chapter 12. Company Profiles

12.1. Teva Pharmaceutical
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Distribution Channel
12.1.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.1.4. Recent Developments and Strategies
12.2. Pfizer
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Distribution Channel
12.2.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.2.4. Recent Developments and Strategies
12.3. Abbott
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Distribution Channel
12.3.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.3.4. Recent Developments and Strategies
12.4. Mallinckrodt Pharmaceuticals
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Distribution Channel
12.4.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.4.4. Recent Developments and Strategies
12.5. Endo International
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Distribution Channel
12.5.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.5.4. Recent Developments and Strategies
12.6. GlaxoSmithKline
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Distribution Channel
12.6.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.6.4. Recent Developments and Strategies
12.7. AstraZeneca
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Distribution Channel
12.7.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.7.4. Recent Developments and Strategies
12.8. Depomed
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Distribution Channel
12.8.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.8.4. Recent Developments and Strategies
12.9. Merck
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Distribution Channel
12.9.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.9.4. Recent Developments and Strategies
12.10. Novartis
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Distribution Channel
12.10.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.10.4. Recent Developments and Strategies

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

Request for Customize Reports
Precedence offers custom market research services that help clients to get information on their business scenario required.

PROCEED TO BUY

   USD 4999
   USD 7999

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence client

Get a Sample
Address: Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com